Vancouver, British Columbia--(Newsfile Corp. - September 18, 2017) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:
18H) (the "Company" or "PreveCeutical") announces that the Company's application to have its common shares listed on
the OTCQB Venture Marketplace ("OTCQB") in the United States has been approved and that the Company's common share began trading on
September 15, 2017, under the symbol "PRVCF".
The OTCQB is for early-stage and developing United States and international companies. To be eligible for trading, companies
must be current in their financial reporting, pass a minimum bid price test and undergo an annual company verification and
management certification process. The OTCQB quality standards provide a strong baseline of transparency, as well as the technology
and regulation to improve the information and trading experience for investors.
PreveCeutical's Chairman and CEO, Mr. Stephen Van Deventer commented, "We are extremely pleased to be able to upgrade to quote
on the OTCQB. This listing will enable us to expand our U.S. shareholder base as well as offer the Company's existing U.S.
shareholders a more transparent and efficient platform to obtain quotes and trade PreveCeutical securities."
About PreveCeutical Medical Inc.
PreveCeutical is a health sciences company that develops innovative preventive therapies utilizing organic and nature identical
products.
PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs,
including: dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel platform for nose to brain
delivery of medical compounds; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a
replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating
athletes who suffer from concussions (mild traumatic brain injury).
PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9® is an oral solution containing polarized and potentiated
essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom.
For more information about PreveCeutical, please visit www.PreveCeutical.com, follow
us on Twitter: http://twitter.com/PreveCeuticals and Facebook: www.facebook.com/PreveCeutical.
On Behalf of the Board of Directors
"Stephen Van Deventer"
Chairman & CEO
For further information, please contact:
Deanna Kress
Director of Corporate Communications & Investor Relations
+1-778-999-6063
deanna@PreveCeutical.com
Forward-Looking Statements:
This news release contains forward-looking statements and forward-looking information (collectively, "forward-looking
statements") within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private
Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are
forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future,
including the Company's anticipated business plans and the prospect of its ability and success in executing its proposed plans.
Often, but not always, forward-looking statements can be identified by words such as "pro forma", "plans", "expects", "may",
"should", "budget", "schedules", "estimates", "forecasts", "intends", "anticipates", "believes", "potential" or variations of such
words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would,
might or will occur or be taken or achieved. Actual results could differ from those projected in any forward-looking statements due
to numerous factors including risks and uncertainties relating to the inability of the Company, to, among other things, obtain any
required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian
Securities Exchange or OTCQB acceptance, as applicable, of any planned future activities, or financing required to carry out its
planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations
and policies affecting the biotechnology or pharmaceutical industry, may also adversely affect the future results or performance of
the Company. These forward-looking statements are made as of the date of this news release and, unless required by applicable law,
the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ
from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans,
expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements,
beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth
herein and should also refer to other periodic reports provided by the Company from time-to-time. These reports and the Company's
filings are available at www.sedar.com.
Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are
cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such
statements.
